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It is well known that there are high levels of response to
treatment topatients with a first episode and early schi-
zophrenia. This outcome is hampered by inadequate
treatment adherence, which leads to relapse, and high
sensitivity to side-effects. Risperidone Long Acting
Injectable (RLAI) treatment has proven to be advanta-
geous compared to oral treatment to these early
patients, both clinically and pharmacoeconomically.
RLAI has proven to improve treatment adherence, pro-
long time to relapse vs. more chronically ill patients, to
improve patient functioning and also to achieve better
symptom control in comparison to oral haloperidol, ris-
peridone and also to patients switched from oral olanza-
pine. Therefore, treatment with atypicals and especially
with RLAI to first episode and early patients can alter
favorably the course of the schizophrenic disorder.
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